Costa M, Schacht A, Mt-Isa S, Saint-Hilary G, Garczarek U, Schmidt H, Boeri M. Learn how to swing: hands on workshop on preference elicitation in the age of personalised medicine. Presented at the 2018 Promoting Statistical Insight (PSI) Conference; June 4, 2018. Amsterdam, Netherlands.

Throughout the development phase of a drug, project teams are faced with many crucial questions: “which efficacy measures best represent clinically meaningful outcomes?”, “which adverse reactions should be monitored closely?”, “what is more important: symptom reduction or fewer adverse events?”. The answers to these questions reflect an element of judgment that could result from stakeholders’ preferences. To achieve greater transparency on how these judgments are formed, preference elicitation studies can be conducted as part of clinical development programs. Recent examples have focused on eliciting preferences from patients, carers and regulators in the context of benefit-risk assessments, but other stakeholders and experts such as physicians and payers, for example, can also be involved. Although regulatory agencies and payers, among others, have started discussions around preference elicitation and how it can be used to support decision-making, statisticians in the pharmaceutical industry have not been very engaged on this topic so far. Preference data in drug development present new challenges for many statisticians. If you have limited experience yourself on this topic, then you are not alone. Join the PSI 2018 workshop on preference elicitation to learn about preference elicitation approaches, to get some hands-on experience with an example of swing weighting and use of relevant software, and to hear about the advantages and challenges characterizing preference elicitation from the design of the study to the analysis of the data.

Share on: